Policy issues in the clinical development and use of immunotherapy for cancer treatment : proceedings of a workshop /
Saved in:
| Author / Creator: | Balogh, Erin, rapporteur. |
|---|---|
| Imprint: | Washington, DC : The National Academies Press, [2016] ©2016 |
| Description: | 1 online resource (1 PDF file (xxii, 112 pages)) : color illustrations |
| Language: | English |
| Subject: | |
| Format: | E-Resource Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/11268731 |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | 11268731 | ||
| 005 | 20210426223003.6 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 161203t20162016dcua ob 100 0 eng | ||
| 016 | 7 | |a 101696946 |2 DNLM | |
| 019 | |a 964337023 |a 968186580 | ||
| 020 | |a 9780309442336 |q (electronic bk.) | ||
| 020 | |a 0309442338 |q (electronic bk.) | ||
| 020 | |z 9780309442329 |q (paperback) | ||
| 020 | |z 030944232X |q (paperback) | ||
| 035 | |a (OCoLC)962446320 |z (OCoLC)964337023 |z (OCoLC)968186580 | ||
| 035 | 9 | |a (OCLCCM-CC)962446320 | |
| 040 | |a NLM |b eng |e rda |e pn |c NLM |d CUS |d MMU |d YDX |d N$T |d OCLCF |d OCLCO |d NLM |d OCLCO |d OCLCA |d BUF |d SNK |d DKU |d BTN |d IGB |d D6H |d VTS |d EZ9 |d VT2 |d AGLDB |d OCLCQ |d OCLCO |d G3B |d S8J |d S9I |d STF |d OCLCQ |d OCLCO |d OCLCA |d UKAHL | ||
| 042 | |a pcc | ||
| 043 | |a n-us--- | ||
| 049 | |a MAIN | ||
| 050 | 4 | |a RC271.I45 | |
| 060 | 0 | 0 | |a 2017 B-202 |
| 060 | 0 | 0 | |a QZ 266 |
| 072 | 7 | |a MED |x 062000 |2 bisacsh | |
| 100 | 1 | |a Balogh, Erin, |e rapporteur. |0 http://id.loc.gov/authorities/names/no2010170659 | |
| 245 | 1 | 0 | |a Policy issues in the clinical development and use of immunotherapy for cancer treatment : |b proceedings of a workshop / |c Erin Balogh, Kimberly Maxfield, Margie Patlak, and Sharyl J. Nass, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Health and Medicine Division, the National Academies of Sciences, Engineering, Medicine. |
| 264 | 1 | |a Washington, DC : |b The National Academies Press, |c [2016] | |
| 264 | 4 | |c ©2016 | |
| 300 | |a 1 online resource (1 PDF file (xxii, 112 pages)) : |b color illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a data file |2 rda | ||
| 504 | |a Includes bibliographical references (pages 94-102). | ||
| 520 | 3 | |a "Immunotherapy is a form of cancer therapy that harnesses the body immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop"--Publisher's description. | |
| 588 | 0 | |a Online resource; title from PDF title page (viewed January 8, 2017). | |
| 650 | 0 | |a Cancer |x Immunotherapy |v Congresses. | |
| 650 | 1 | 2 | |a Neoplasms |x immunology. |0 https://id.nlm.nih.gov/mesh/D009369Q000276 |
| 650 | 1 | 2 | |a Neoplasms |x therapy. |0 https://id.nlm.nih.gov/mesh/D009369Q000628 |
| 650 | 2 | 2 | |a Immunotherapy. |0 https://id.nlm.nih.gov/mesh/D007167 |
| 650 | 2 | 2 | |a Immunotherapy |x adverse effects. |0 https://id.nlm.nih.gov/mesh/D007167Q000009 |
| 650 | 7 | |a MEDICAL |x Oncology. |2 bisacsh | |
| 650 | 7 | |a Cancer |x Immunotherapy. |2 fast |0 (OCoLC)fst00845386 | |
| 655 | 2 | |a Congress. |0 https://id.nlm.nih.gov/mesh/D016423 | |
| 655 | 4 | |a Electronic books. | |
| 655 | 7 | |a Conference papers and proceedings. |2 fast |0 (OCoLC)fst01423772 | |
| 700 | 1 | |a Maxfield, Kimberly, |e rapporteur. | |
| 700 | 1 | |a Patlak, Margie, |e rapporteur. |0 http://id.loc.gov/authorities/names/n2002014880 | |
| 700 | 1 | |a Nass, Sharyl J., |e rapporteur. |0 http://id.loc.gov/authorities/names/n2001127655 | |
| 710 | 2 | |a National Cancer Policy Forum (U.S.), |e sponsoring body. |0 http://id.loc.gov/authorities/names/n2006183479 | |
| 711 | 2 | |a Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment (Workshop) |d (2016 : |c Washington, D.C.) |0 http://id.loc.gov/authorities/names/no2016154002 | |
| 776 | 0 | 8 | |i Print version: |t Policy issues in the clinical development and use of immunotherapy for cancer treatment. |d Washington : National Academies Press, 2016 |z 030944232X |w (OCoLC)955020058 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.17226/23497 |y National Academies Press |
| 856 | 4 | 0 | |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=e000xna&AN=1426563 |y eBooks on EBSCOhost |
| 903 | |a HeVa | ||
| 929 | |a oclccm | ||
| 999 | f | f | |i 670ac6dc-6a71-55bd-bc2c-e2052e565133 |s 39faa275-c61d-58a0-9f19-f17c303335b6 |
| 928 | |t Library of Congress classification |a RC271.I45 |l Online |c UC-FullText |u http://dx.doi.org/10.17226/23497 |z National Academies Press |g ebooks |i 12445795 | ||
| 928 | |t Library of Congress classification |a RC271.I45 |l Online |c UC-FullText |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=e000xna&AN=1426563 |z eBooks on EBSCOhost |g ebooks |i 12445796 | ||